81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases. Issue 1 (January 2015) - Gettinger, S.N.; Bazhenova, L.; Salgia, R.; Langer, C.J.; Gold, K.A.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Narasimhan, N.I.; Dorer, D.J.; Rivera, V.M.; Clackson, T.; et al.